IL252036B - Pyrimidine or pyridine compounds, a method for their preparation and pharmaceutical uses thereof - Google Patents

Pyrimidine or pyridine compounds, a method for their preparation and pharmaceutical uses thereof

Info

Publication number
IL252036B
IL252036B IL252036A IL25203617A IL252036B IL 252036 B IL252036 B IL 252036B IL 252036 A IL252036 A IL 252036A IL 25203617 A IL25203617 A IL 25203617A IL 252036 B IL252036 B IL 252036B
Authority
IL
Israel
Prior art keywords
pyrimidine
preparation
method therefor
pyridine compounds
pharmaceutical uses
Prior art date
Application number
IL252036A
Other languages
English (en)
Hebrew (he)
Other versions
IL252036A0 (en
Original Assignee
Inventisbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54566905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL252036(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inventisbio Co Ltd filed Critical Inventisbio Co Ltd
Publication of IL252036A0 publication Critical patent/IL252036A0/en
Publication of IL252036B publication Critical patent/IL252036B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL252036A 2014-11-05 2017-04-30 Pyrimidine or pyridine compounds, a method for their preparation and pharmaceutical uses thereof IL252036B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410619334 2014-11-05
CN201510152615.0A CN105085489B (zh) 2014-11-05 2015-04-01 嘧啶或吡啶类化合物、其制备方法和医药用途
PCT/CN2015/093815 WO2016070816A1 (zh) 2014-11-05 2015-11-05 嘧啶或吡啶类化合物、其制备方法和医药用途

Publications (2)

Publication Number Publication Date
IL252036A0 IL252036A0 (en) 2017-06-29
IL252036B true IL252036B (en) 2021-09-30

Family

ID=54566905

Family Applications (2)

Application Number Title Priority Date Filing Date
IL252036A IL252036B (en) 2014-11-05 2017-04-30 Pyrimidine or pyridine compounds, a method for their preparation and pharmaceutical uses thereof
IL286165A IL286165B2 (en) 2014-11-05 2021-09-05 Pyrimidine or pyridine compounds, a method for their preparation and pharmaceutical uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL286165A IL286165B2 (en) 2014-11-05 2021-09-05 Pyrimidine or pyridine compounds, a method for their preparation and pharmaceutical uses thereof

Country Status (9)

Country Link
US (5) US10179784B2 (enExample)
EP (2) EP3885344B1 (enExample)
JP (1) JP6637058B2 (enExample)
KR (1) KR102560052B1 (enExample)
CN (5) CN111170998B (enExample)
CA (1) CA2966376C (enExample)
ES (1) ES2881622T3 (enExample)
IL (2) IL252036B (enExample)
WO (1) WO2016070816A1 (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015188777A1 (en) * 2014-06-12 2015-12-17 Shanghai Fochon Pharmaceutical Co Ltd Certain protein kinase inhibitors
CN113121575A (zh) * 2014-08-25 2021-07-16 四川海思科制药有限公司 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途
HUE055233T2 (hu) * 2014-10-11 2021-11-29 Shanghai Hansoh Biomedical Co Ltd Az EGFR gátló és annak elkészítése és alkalmazása
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
WO2016094821A2 (en) * 2014-12-11 2016-06-16 Beta Pharma, Inc. Substituted 2-anilinopyrimidine derivatives as egfr modulators
WO2016105525A2 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Novel pyrimidines as egfr inhibitors and methods of treating disorders
AU2016292450B2 (en) * 2015-07-16 2021-03-25 Centaurus Biopharma Co., Ltd. Aniline pyrimidine derivatives and uses thereof
JP6606278B2 (ja) 2015-08-31 2019-11-13 ウーシー ショアンリャン バイオテクノロジー カンパニー，リミティド ２−アリールアミノピリジン、ピリミジン又はトリアジン誘導体及びその製造方法と使用
CN106117185B (zh) * 2015-08-31 2017-11-07 广州必贝特医药技术有限公司 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用
CN106749193B (zh) * 2015-11-23 2020-11-20 南京圣和药业股份有限公司 吲唑取代的表皮生长因子受体抑制剂及其应用
CN106188138B (zh) * 2015-12-02 2018-07-24 深圳市塔吉瑞生物医药有限公司 一种二氨基嘧啶化合物及包含该化合物的组合物
JP6605751B2 (ja) * 2015-12-27 2019-11-13 ノイフォルム・ファーマシューティカルズ・インコーポレイテッド がん状を治療するための重水素化合物
CN106928150B (zh) * 2015-12-31 2020-07-31 恩瑞生物医药科技（上海）有限公司 丙烯酰胺苯胺衍生物及其药学上的应用
US10435388B2 (en) * 2016-01-07 2019-10-08 Cs Pharmatech Limited Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase
CN106995435B (zh) * 2016-01-22 2018-06-08 焦玉奇 2-(2,4,5-取代苯胺)嘧啶衍生物
CN107043369A (zh) * 2016-02-06 2017-08-15 焦玉奇 2‑(2,4,5‑取代苯胺)嘧啶衍生物
CN107188888A (zh) * 2016-03-15 2017-09-22 罗欣生物科技（上海）有限公司 一种制备甲磺酸迈瑞替尼的方法
CN106279160B (zh) * 2016-03-18 2017-09-26 海南越康生物医药有限公司 N‑苯基‑2‑氨基嘧啶类化合物制备方法和用途
CN105884687B (zh) * 2016-04-14 2018-06-22 梯尔希（南京）药物研发有限公司 一种5-苄基苄达明的制备方法
SG11201809931YA (en) * 2016-05-11 2018-12-28 Beta Pharma Inc 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
KR102444835B1 (ko) * 2016-05-26 2022-09-19 리커리엄 아이피 홀딩스, 엘엘씨 Egfr 억제제 화합물
TW201800404A (zh) * 2016-06-17 2018-01-01 貝達醫藥公司 N-(2-(2-(二甲基胺基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)胺基)苯基)丙烯醯胺及其結晶型式之醫藥鹽
CN107540661A (zh) * 2016-06-24 2018-01-05 正大天晴药业集团股份有限公司 作为egfr抑制剂的苯胺嘧啶化合物的结晶
EP3492462B1 (en) * 2016-07-26 2023-08-30 Shenzhen TargetRx, Inc. Amino pyrimidine compound for inhibiting protein tyrosine kinase activity
CN107840846B (zh) * 2016-09-19 2020-11-24 郑州泰基鸿诺医药股份有限公司 一种含嘧啶环的化合物、egfr抑制剂及其应用
CN107973783B (zh) * 2016-10-21 2024-09-06 正大天晴药业集团股份有限公司 作为erk抑制剂的苯胺嘧啶衍生物
CN113896718A (zh) * 2016-10-21 2022-01-07 正大天晴药业集团股份有限公司 一种三氟乙基取代吲哚的苯胺嘧啶化合物及其盐的结晶
CN108057036B (zh) * 2016-11-07 2023-06-13 正大天晴药业集团股份有限公司 一种egfr抑制剂的固体药物组合物
CN106957304B (zh) * 2017-04-25 2017-12-01 孔令廷 一种石墨烯负载FeCl3催化剂的制备方法及其在制备抗癌药物中间体的用途
MY199042A (en) * 2017-06-13 2023-10-11 Beijing Adamadle Biotechnology Llc Aminopyrimidine compound, preparation method therefor and use thereof
US11180478B2 (en) * 2017-06-16 2021-11-23 Beta Pharma, Inc. Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
CN107266437B (zh) 2017-07-19 2019-08-30 海南越康生物医药有限公司 N-苯基-2-氨基嘧啶类化合物的晶型、盐型及其制备方法
CN107721991B (zh) * 2017-11-17 2019-10-18 南方医科大学中西医结合医院 一种6-(嘧啶-4-基)-1h-吲唑衍生物及其制备方法和应用
CN107935995A (zh) * 2017-11-28 2018-04-20 中山大学 一种新型2‑苯胺基嘧啶衍生物及其在制备抗肿瘤药物中的应用
JP2021507123A (ja) 2017-12-20 2021-02-22 ビーエイエスエフ・ソシエタス・エウロパエアＢａｓｆ Ｓｅ 金属含有膜の生成方法
CN108558832B (zh) * 2018-01-17 2021-04-30 浙江树人学院 一种新型抗肿瘤药物奥希替尼衍生物及其制备方法
CN110272420A (zh) * 2018-03-16 2019-09-24 江苏正大丰海制药有限公司 氘代3-(4,5-取代氨基嘧啶)苯基化合物单甲磺酸盐晶型及其制备方法
WO2019218987A1 (en) * 2018-05-15 2019-11-21 Inventisbio Shanghai Ltd. Egfr inhibitors
CN108675993A (zh) * 2018-06-14 2018-10-19 纽瑞森生物科技（北京）有限公司 氘代嘧啶类化合物、制备方法、药物组合物、制剂和用途
MX2020013808A (es) * 2018-06-18 2021-05-27 UCB Biopharma SRL Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
CN110698461B (zh) * 2018-07-09 2024-04-05 上海翰森生物医药科技有限公司 第三代egfr抑制剂的制备方法
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
US10376512B1 (en) 2018-08-09 2019-08-13 Chia Tai Tianqing Pharmaeutical Group Co., Ltd. Crystal of aniline pyrimidine compound of trifluoroethyl substituted indole and salt thereof
WO2020119739A1 (zh) * 2018-12-12 2020-06-18 暨南大学 2-氨基嘧啶类化合物及其应用
CN111410667B (zh) * 2019-01-08 2024-11-22 武汉宇科源医药生物科技有限公司 新型(1,2,4)三唑并(1,5-a)吡啶基磷氧化物及其用途
MX2021010115A (es) 2019-02-22 2021-09-21 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda.
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
CN111747931A (zh) * 2019-03-29 2020-10-09 深圳福沃药业有限公司 用于治疗癌症的氮杂芳环酰胺衍生物
CN110016017A (zh) * 2019-05-16 2019-07-16 益方生物科技（上海）有限公司 一类嘧啶化合物的盐、多晶型物及其药物组合物、制备方法和应用
WO2020245208A1 (en) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
AU2020296620B2 (en) * 2019-06-20 2023-07-13 Oncobix Co.Ltd. Pyrimidine derivative inhibiting growth of cancer cell and medicinal use thereof
CN110229143A (zh) * 2019-06-21 2019-09-13 益方生物科技（上海）有限公司 一类嘧啶化合物的盐、多晶型物及其药物组合物、制备方法和应用
EP3991733A4 (en) 2019-06-27 2023-07-05 Hanmi Pharm. Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPY AGENTS
CN114430681A (zh) * 2019-09-23 2022-05-03 贝达医药公司 使用egfr和cdk4/6抑制剂的组合治疗egfr突变相关的癌症
WO2021066443A1 (ko) * 2019-09-30 2021-04-08 한미약품 주식회사 Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN113179640B (zh) * 2019-11-26 2024-06-25 上海翰森生物医药科技有限公司 含氮多环类衍生物抑制剂、其制备方法和应用
CN110898026A (zh) * 2019-12-11 2020-03-24 倍而达药业（苏州）有限公司 包含bpi-7711的药用组合物及其制备方法
CN111100117B (zh) * 2019-12-18 2021-02-19 上海倍而达药业有限公司 氨基嘧啶类化合物甲磺酸盐的晶型a及其制备方法和应用
CN111057073A (zh) * 2019-12-26 2020-04-24 浙江工业大学 一种4-吲哚-2-芳胺基嘧啶化合物及其在炎症治疗中的应用
KR20220130190A (ko) 2020-01-20 2022-09-26 아스트라제네카 아베 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113354622B (zh) * 2020-03-06 2022-11-01 沈阳药科大学 对苯二胺类lsd1抑制剂及其制备方法
US12509441B2 (en) 2020-03-13 2025-12-30 Tyk Medicines (Zhengzhou), Inc. Compounds used as kinase inhibitors and application thereof
CN113493419A (zh) * 2020-03-18 2021-10-12 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
WO2021243596A1 (en) * 2020-06-03 2021-12-09 InventisBio Co., Ltd. Aminopyrimidine compounds, preparation methods and uses thereof
AU2021341258A1 (en) * 2020-09-08 2023-04-13 Betta Pharmaceuticals Co., Ltd. CD73 inhibitor and application thereof in medicine
CN112079728B (zh) * 2020-09-17 2022-08-19 苏州昊帆生物股份有限公司 氘代n,n,n’-三甲基乙二胺类化合物及其制备方法
CN112174870B (zh) * 2020-10-12 2023-07-21 蔡霈 (r)-1-烷烃酰基-2-取代吡咯烷-2-甲酰胺的制备方法及其药用用途
CA3196068A1 (en) * 2020-12-02 2022-06-09 Abbisko Therapeutics Co., Ltd 2,3-dihydro-1h-pyrrolo[3,2-b]pyridine derivative, preparation method therefor, and application thereof
CN112451527B (zh) * 2020-12-02 2022-08-16 北京鞍石生物科技有限责任公司 氨基嘧啶类化合物的用途
CN117561254A (zh) * 2021-04-30 2024-02-13 苏州浦合医药科技有限公司 用于肺癌治疗的嘧啶基氨基苯
CN116670126A (zh) * 2021-05-13 2023-08-29 上海和誉生物医药科技有限公司 具有egfr抑制活性的氮杂芳基衍生物、其制备方法和应用
AU2022312430A1 (en) * 2021-07-13 2024-02-29 ACEA Therapeutics, Inc. Heterocyclic compounds and uses thereof
CN113387935B (zh) * 2021-07-23 2022-06-10 苏州雅深智慧科技有限公司 抑制三突变表皮生长因子受体酪氨酸激酶的化合物及用途
WO2023011415A1 (zh) * 2021-08-02 2023-02-09 贝达药业股份有限公司 Egfr抑制剂的药物组合及其应用
US20240327402A1 (en) * 2021-08-06 2024-10-03 Abbisko Therapeutics Co., Ltd. Pyrimidine or pyridine derivative, preparation method therefor, and application thereof in pharmacy
CN113773305B (zh) * 2021-09-16 2023-08-11 中国人民解放军军事科学院军事医学研究院 一种氨基嘧啶衍生物及其作为egfr酪氨酸激酶抑制剂的应用
AU2023246862A1 (en) 2022-03-31 2024-10-31 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
IL317733A (en) 2022-06-27 2025-02-01 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for cancer treatment
WO2024008048A1 (zh) * 2022-07-04 2024-01-11 杭州德睿智药科技有限公司 新型嘧啶或三嗪取代吡啶并杂环化合物
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
WO2024094064A1 (en) * 2022-11-02 2024-05-10 Suzhou Puhe Biopharma Co., Ltd Pyrimidinylaminobenzenes for treating lung cancer with distant metastasis
CN115925687B (zh) * 2022-12-29 2024-04-02 广东省人民医院 靶向egfr的化合物、pet分子探针及其制备方法与应用
CN117623937A (zh) * 2023-10-20 2024-03-01 金凯(辽宁)生命科技股份有限公司 一种n,n,n'-三甲基乙二胺的制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001237041B9 (en) * 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
WO2008051757A1 (en) * 2006-10-20 2008-05-02 Irm Llc Compositions and methods for modulating c-kit and pdgfr receptors
EP2079729A1 (en) * 2006-11-03 2009-07-22 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008072634A1 (ja) * 2006-12-12 2008-06-19 Takeda Pharmaceutical Company Limited 縮合複素環化合物
CN101568530A (zh) 2006-12-22 2009-10-28 诺瓦提斯公司 吲哚-4-基-嘧啶-2-基胺衍生物及其作为细胞周期蛋白依赖性激酶抑制剂的用途
WO2008079933A2 (en) 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
TWI552752B (zh) 2007-10-19 2016-10-11 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
TWI546290B (zh) * 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
US9155422B1 (en) * 2008-09-24 2015-10-13 Susan M. Wohld Turkey flipper and method for making and using
CN101723936B (zh) * 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
SG196784A1 (en) 2008-12-03 2014-02-13 Scripps Research Inst Stem cell cultures
CA2760794C (en) 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
MX340670B (es) 2009-08-25 2016-07-20 Abraxis Bioscience Llc * Terapia combinada con composiciones de nanoparticulas de taxano e inhibidores de hedgehog.
US20130137709A1 (en) * 2010-05-05 2013-05-30 Nathanael S. Gray Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
US8916577B2 (en) 2011-01-26 2014-12-23 Nerviano Medical Sciences S.R.L. Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
US20140303163A1 (en) * 2011-03-24 2014-10-09 Ying Luo Use of kinase inhibitors in preventing and treating inflammatory disorder
EP2704572B1 (en) * 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
CN102363618A (zh) * 2011-07-04 2012-02-29 华东理工大学 一种表皮生长因子受体的新型抑制剂及其应用
BR112014001768B1 (pt) * 2011-07-27 2019-02-05 Astrazeneca Ab composto n-(2-{2-dimetilaminoetil-metilamino}-4-metóxi-5-{[4-(1-metilindol-3-il) pirimidin-2-il]amino}fenil) prop-2-enamida ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso do dito composto
MD20140023A2 (ro) 2011-09-22 2014-06-30 Pfizer Inc. Derivaţi de pirolpirimidină şi purină
LT2805940T (lt) 2012-01-17 2017-01-10 Astellas Pharma Inc. Pirazino karboksamido junginys
CN103360407B (zh) * 2012-04-10 2016-06-22 上海希迈医药科技有限公司 一种噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
CN103374000B (zh) 2012-04-13 2015-11-11 中国科学院广州生物医药与健康研究院 嘧啶并二氮杂卓类化合物及其药用组合物和应用
WO2013184766A1 (en) 2012-06-06 2013-12-12 Irm Llc Compounds and compositions for modulating egfr activity
US10112927B2 (en) * 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3181564B1 (en) * 2012-11-20 2019-09-18 H. Hoffnabb-La Roche Ag Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
CN104761544B (zh) 2014-01-03 2019-03-15 北京轩义医药科技有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
CN104860941B (zh) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CN103804303B (zh) 2014-03-13 2015-04-08 山东理工大学 Egfr小分子抑制剂嘧啶衍生物及其制备方法与用途
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
WO2015188777A1 (en) 2014-06-12 2015-12-17 Shanghai Fochon Pharmaceutical Co Ltd Certain protein kinase inhibitors
DK3157916T3 (en) * 2014-06-19 2019-03-18 Ariad Pharma Inc HETEROARYL COMPOUNDS FOR CHINESE INHIBITION
CN105254615B (zh) 2014-07-11 2017-02-22 杭州华东医药集团新药研究院有限公司 苯胺嘧啶衍生物及其在制备抗恶性肿瘤药物中的用途
CN105315285B (zh) 2014-07-25 2017-12-08 上海海雁医药科技有限公司 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
CN104140418B (zh) 2014-08-15 2016-08-24 常州润诺生物科技有限公司 2-(2，4，5-取代苯胺)嘧啶衍生物及其用途
CN113121575A (zh) * 2014-08-25 2021-07-16 四川海思科制药有限公司 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途
CN105461695B (zh) 2014-09-29 2018-03-27 齐鲁制药有限公司 嘧啶或三嗪衍生物及其制备方法和用途
CN105237515B (zh) 2014-10-10 2018-06-05 益方生物科技（上海）有限公司 氘代嘧啶类化合物、其制备方法、药物组合物和用途
HUE055233T2 (hu) 2014-10-11 2021-11-29 Shanghai Hansoh Biomedical Co Ltd Az EGFR gátló és annak elkészítése és alkalmazása
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
WO2016094821A2 (en) 2014-12-11 2016-06-16 Beta Pharma, Inc. Substituted 2-anilinopyrimidine derivatives as egfr modulators
WO2016105525A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Novel pyrimidines as egfr inhibitors and methods of treating disorders
AU2016292450B2 (en) 2015-07-16 2021-03-25 Centaurus Biopharma Co., Ltd. Aniline pyrimidine derivatives and uses thereof
CN105001208A (zh) 2015-08-06 2015-10-28 南京雷科星生物技术有限公司 一种表皮生长因子受体egfr抑制剂及其制备方法与用途
CN105153122B (zh) 2015-08-27 2018-07-20 上海圣考医药科技有限公司 [(吲哚-3-基)嘧啶-2-基]氨基苯基丙-2-烯酰胺衍生物及盐、制备方法、应用
CN107540661A (zh) 2016-06-24 2018-01-05 正大天晴药业集团股份有限公司 作为egfr抑制剂的苯胺嘧啶化合物的结晶

Also Published As

Publication number Publication date
KR20170101908A (ko) 2017-09-06
IL286165B1 (en) 2023-03-01
CN115403565B (zh) 2023-11-28
IL286165A (en) 2021-10-31
US20170355696A1 (en) 2017-12-14
EP3885344A3 (en) 2021-12-08
CN110054618B (zh) 2022-09-20
JP2017533266A (ja) 2017-11-09
EP3885344B1 (en) 2025-03-26
CN107548391A8 (zh) 2019-01-11
EP3216786A1 (en) 2017-09-13
US11498921B1 (en) 2022-11-15
US10179784B2 (en) 2019-01-15
US20210261543A1 (en) 2021-08-26
CN107548391A (zh) 2018-01-05
CN105085489A (zh) 2015-11-25
CN111170998B (zh) 2023-04-11
CN111170998A (zh) 2020-05-19
EP3216786B1 (en) 2021-05-12
JP6637058B2 (ja) 2020-01-29
US11203589B2 (en) 2021-12-21
CN107548391B (zh) 2023-05-26
CN110054618A (zh) 2019-07-26
HK1243702A1 (en) 2018-07-20
KR102560052B1 (ko) 2023-07-25
CN115403565A (zh) 2022-11-29
CA2966376A1 (en) 2016-05-12
EP3216786A4 (en) 2018-07-04
CA2966376C (en) 2024-01-30
WO2016070816A1 (zh) 2016-05-12
US20190152969A1 (en) 2019-05-23
US20240208967A1 (en) 2024-06-27
IL286165B2 (en) 2023-07-01
CN105085489B (zh) 2019-03-01
IL252036A0 (en) 2017-06-29
ES2881622T3 (es) 2021-11-30
EP3885344A2 (en) 2021-09-29

Similar Documents

Publication Publication Date Title
IL286165B1 (en) Pyrimidine or pyridine compounds, a method for their preparation and pharmaceutical uses thereof
PL3181560T3 (pl) Pochodna pirydynoamidopirymidyny, sposób jej otrzymywania i zastosowanie
EP3138839A4 (en) Pyridone or pyrimidone derivative, preparation method therefor and application thereof
IL252346A0 (en) Heteroaryl compounds, their preparation and use
EP3268362A4 (en) Substituted pyridines and uses thereof
EP3126362A4 (en) Anti-fibrotic pyridinones
EP3102171A4 (en) Systems, methods, and devices for assisting walking for developmentally-delayed toddlers
EP3097078A4 (en) Pyridines and pyrimidines and use thereof
EP3115361A4 (en) Heterocyclic compounds, and preparation method and use thereof
EP3218098A4 (en) Microreactor systems and methods
IL290114A (en) Pharmaceutical preparations, their preparation and uses
EP3231802A4 (en) Pyridinecarboxamide derivatives, preparation method therefor and pharmaceutical uses thereof
ZA201805600B (en) Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof
GB201408673D0 (en) Medicaments,uses and methods
EP3093296A4 (en) Fuc3s4s substituted oligoglycosaminoglycan and preparation method thereof
PT3166945T (pt) Derivados de triazolopirimidinona ou de triazolopiridinona inovadores e utilização dos mesmos
IL252397A0 (en) Pharmaceutical preparations, their preparation and uses
EP3157016A4 (en) Scintillator, preparing method thereof, and application thereof
PL3229843T3 (pl) Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
EP3154547A4 (en) Pyrimidine compounds and methods using the same
IL252461A0 (en) Alpha-asrylaldehyde ester, a method for its preparation and application
EP3235816A4 (en) 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof
EP3130588A4 (en) Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition
PT3228616T (pt) Derivados de piridina
HK1260336A1 (en) Valbenazine salts and polymorphs thereof